A Randomised, Double-blind (Within Dose Groups), Parallel Group, Placebocontrolled Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Rising Doses (50 mg, 200 mg, 400 mg) of BI 671800 HEA in Chinese Healthy Male Volunteers and Multiple Rising Doses (50 mg b.i.d., 200 mg b.i.d., 400 mg b.i.d.) of BI 671800 HEA in Japanese Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2015
At a glance
- Drugs BI 671800 (Primary)
- Indications Allergic rhinitis; Asthma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 16 Oct 2015 Last checked against ClinicalTrials.gov record.
- 14 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2010 New trial record